Zealand Pharma signs up to $1.3 billion AI partnership with Generate Biomedicines for protein-based obesity drugs

Zealand Pharma announced a partnership with Generate Biomedicines to develop new protein-based treatments targeting obesity and related metabolic conditions.

The collaboration will use Generate's artificial-intelligence platform to design novel protein therapeutics, aiming to speed discovery and improve efficacy.

The deal is valued at up to $1.3 billion, with Zealand providing an upfront payment of $30 million for the first two projects.